Density of high endothelial venules and PDL-1 expression: relationship with tumor-infiltrating lymphocytes in primary cutaneous melanomas
Open Access
- 1 January 2024
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 96 (1) , e20230441
Abstract
Studies have highlighted melanoma immunogenicity, and the prognostic importance of tumor infiltrating lymphocytes (TILs) and mechanisms of tumor immune evasion, such as hyperexpression of programmed cell death ligand 1 (PDL-1). High endothelial venules (HEV) are specialized blood vessels that can facilitate the lymphocytes migration to the tumor. Here we evaluate the association of HEV density and PDL-1 expression in primary cutaneous melanomas with the presence and degree of TILs and with other clinicopathological variables (age, sex, tumor location, melanoma histological type, Breslow thickness, ulceration, regression signs, mitotic index). HEV density and PDL-1 expression were assessed immunohistochemically in 78 melanoma cases, using a specific antibody, and were detected in 59% and 76% of these, respectively. Positive associations were identified between HEV density and PDL-1 expression with the presence and degree of lymphocytic infiltration, melanoma histological type and ulceration presence. No correlation was found between HEV density and PDL-1 expression. Our findings confirm the HEV role in the recruitment and facilitation of lymphocyte transport in cutaneous melanomas, where HEV density is strongly associated with the degree of TILs. Additionally, PDL-1 hyperexpression suggests a possible mechanism of tumor immune evasion, which may lead to inactivation and reduction of the tumor lymphocytes number.Keywords
This publication has 54 references indexed in Scilit:
- Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapyCancer Cell, 2022
- High endothelial venules (HEVs) in immunity, inflammation and cancerAngiogenesis, 2021
- 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and BeyondEBioMedicine, 2015
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerBreast Cancer Research and Treatment, 2014
- Overall survival and PD‐L1 expression in metastasized malignant melanomaCancer, 2010
- Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanomaCancer, 2010
- Tumor progression by immune evasion in melanomaCancer, 2010
- Association of microvessel density with infiltrating cells in human cutaneous malignant melanomaPathology and Oncology Research, 2007
- A comparative study of endothelial cell markers expressed in chronically inflamed human tissues: MECA‐79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146The Journal of Pathology, 2005
- Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanomaCancer, 1996